urofollitropin + metformin

Urofollitropin + metformin is a combination therapy investigated for the treatment of infertility in women with Polycystic Ovary Syndrome (PCOS), particularly those who are resistant to clomiphene citrate. Urofollitropin is a highly purified preparation of follicle-stimulating hormone (FSH) extracted from the urine of postmenopausal women, which acts directly on the ovaries to stimulate the development and maturation of follicles. Metformin is a biguanide insulin sensitizer that addresses the hyperinsulinemia and insulin resistance frequently associated with PCOS. By improving insulin sensitivity, metformin helps to normalize the intraovarian environment, reduce androgen levels, and enhance the ovarian response to gonadotropin stimulation. This combination is often used in protocols involving controlled ovarian hyperstimulation and intrauterine insemination (IUI) to improve ovulation and pregnancy rates while potentially reducing the risk of ovarian hyperstimulation syndrome (OHSS).

Other names

urinary follicle stimulating hormone + metforminuFSH + metforminFSH + metformin